2020 Targeted Translation Research Accelerator

TIMELINE

ASAP: Notice of Intent (NOI) registration OPEN. *Please contact MRFF team to discuss the suitability of your project.*
TBA 2020: 1st Draft of Project Plan, budget and required attachments to MRFF team for review. Early submission encouraged.
TBA 2020: UoM lead application - Final Draft and all atatchments to MRFF team for review, including draft of CEO letter detailed UoM letter of support and completed Authority to Participate form (this will enable MRFF team to obtain signature of DVCR on the UoM letter of support)
TBA 2020: UoM as partner - Provide partners draft proposal (including project plan, budget, IP arrangements), draft partner letter of support to request sign off by the partner organisation and completed Authority to Participate form
TBA 2020: Complete entry of online application details and assessment criteria for compliance check
Monday, 22 April 2020: Submit application to sponsor before 5pm

Overview

The objective of this 2020 Targeted Translation Research Accelerator grant opportunity is to support the development of novel preventive, diagnostic and therapeutic approaches and products for diabetes and cardiovascular disease.

The expected outcome of the research funded through partnership projects with the independent organisation selected under this grant opportunity is to improve knowledge and its translation into practice in order to reduce the burden of diabetes and cardiovascular disease.

The successful independent organisation will be responsible for ensuring that the Accelerator:

establishes through competitive processes two research centres, one for diabetes and one for cardiovascular disease to accelerate therapies for the prevention, early detection and treatment of disease related complications
supports through competitive processes research projects on the potential common pathways interactions, and complexities for patients experiencing two or more of the following: Type 1 diabetes; Type 2 diabetes; and cardiovascular disease
targets investment and related support through partnership projects to progress promising drug and device development projects, with a focus on promoting commercialisation of novel therapeutics and devices for diabetes and cardiovascular disease
sources, nurtures, and invests in early stage therapeutic research targets to transform diagnostic and therapeutic care for people with diabetes
commissions and conducts research to support the health and commercial sectors to deliver transformations in diabetes and cardiovascular disease.

Funding

For this grant opportunity, up to $47 million is available over four years from 2019-20 to 2022-23. There is the potential for this grant to be extended up to a maximum of 10 years.

$6.5 million in 2019-20
$12.5 million in 2020-21
$12.5 million in 2021-22
$15.5 million in 2022-23

The grant amount will be up to 100 per cent of eligible project costs (grant percentage).

You must complete your project by 31 January 2025.

Eligibility

Applications must provide evidence from your board (or chief executive officer or equivalent if there is no board) that the project is supported, and that you can complete the project and meet the costs of the project not covered by grant funding

To be eligible, your project must:

be aimed at the objectives in section 1.3
have at least but no more than $47million in eligible expenditure

How to apply

Notice of Intent: Please register your Notice of Intent if you are considering applying for the 2020 Targeted Translation Research Accelerator grant opportunity. RIC team will then contact each applicant with further information.
Review documentation: Review the 2020 Targeted Translation Research Accelerator grant guidelines available below.
Contact: Contact the MRFF team to discuss the suitability of your project.
Create online application: via business.gov.au
Submit first draft application to RIC: Provide draft of proposal, letter of support and all required attachements (as per section 6.1 of the Grant Guidelines) to RIC within the RIC internal submission period for review.
Submit Authority to Participate form which includes:
* names of all key UoM investigators and roles
* name of lead organization and partners
HoD signature or approval required for all involved departments with participating investigators.
Signed ATP to be sent to enquiries-mrff@unimelb.edu.au
Complete application: After taking feedback from the RIC team into consideration, complete the application on the portal. It is suggested advice is sought from colleagues, Faculty Mentors, etc. before finalising the application.
Finalise details in application for compliance review by RIC: email login details to RIC at enquiries-mrff@unimelb.edu.au to obtain an online application form and document upload check for compliance.
Final submission: Submit the application on the online portal.
Sent a copy of your final application to RIC at enquiries-mrff@unimelb.edu.au